Truong Dinh Quang, Darwish Ahmed A, Gras Jérémie, Wieërs Grégoire, Cornet Anne, Robert Annie, Mourad Michel, Malaise Jacques, de Ville de Goyet Jean, Reding Raymond, Latinne Dominique
Pediatric Liver Transplant Program, Saint-Luc University Clinics, Université Catholique de Louvain, Brussels, Belgium.
Transpl Immunol. 2007 Jun;17(4):283-7. doi: 10.1016/j.trim.2007.01.007. Epub 2007 Feb 2.
Analysing the relevance of soluble CD30 (sCD30) in the bloodstream before and after transplantation may be important for the monitoring of transplant recipients. In this study, 27 patients (15 pediatric liver and 12 adult kidney graft recipients) were investigated. In the liver graft group, the patients who developed acute rejection during the first month (n=9) had a slightly higher sCD30 value on pre-transplantation baseline (day 0) and post-transplantation day 7, when compared to patients with normal graft function (n=6) (day 0: 102(1.6) U/ml versus 118(1.5) U/ml, p=0.52) and (day 7: 69(1.5) U/ml versus 83(1.6) U/ml, p=0.47). Increased serum sCD30 was shown to correlate with increased interleukin-10 circulating levels between day 0 and day 7 (r=0.53; p=0.04), whereas, no correlation could be evidenced between interferon-gamma (IFN-gamma) and sCD30 (r=0.02; p=0.47). Similarly, in the kidney transplantation group, no significant difference was found in sCD30 levels at day 0 in both groups with graft rejection or normal graft function (n=6) (85(1.3) U/ml versus 77(1.6) U/ml, p=0.66), but sCD30 decreased significantly at day 7 post-transplantation from baseline value in the rejection group (n=6) (77(1.6) versus 35(1.4); p=0.02). We conclude that increased serum sCD30 was correlated with increased IL-10 (interleukin-10) circulating levels, but not with IFN-gamma levels in the post-transplantation period. Neither pre-transplantation sCD30 nor sCD30 at day 7 post-transplantation could be correlated with acute rejection in liver graft recipient. The monitoring of sCD30 might constitute a tool to assess the risk of acute rejection in renal transplant but did not appear as a valuable mean for early immunological monitoring in the small group of liver allograft recipients patients analysed in this study.
分析移植前后血液中可溶性CD30（sCD30）的相关性对于监测移植受者可能很重要。在本研究中，对27例患者（15例小儿肝移植受者和12例成人肾移植受者）进行了调查。在肝移植组中，与移植功能正常的患者（n = 6）相比，在移植后第一个月发生急性排斥反应的患者（n = 9）在移植前基线（第0天）和移植后第7天的sCD30值略高（第0天：102(1.6) U/ml对118(1.5) U/ml，p = 0.52）以及（第7天：69(1.5) U/ml对83(1.6) U/ml，p = 0.47）。结果显示，血清sCD30升高与第0天至第7天循环中白细胞介素-10水平升高相关（r = 0.53；p = 0.04），而干扰素-γ（IFN-γ）与sCD30之间无相关性（r = 0.02；p = 0.47）。同样，在肾移植组中，移植排斥组和移植功能正常组（n = 6）在第0天的sCD30水平无显著差异（85(1.3) U/ml对77(1.6) U/ml，p = 0.66），但在移植后第7天，排斥组（n = 6）的sCD30从基线值显著下降（77(1.6)对35(1.4)；p = 0.02）。我们得出结论，血清sCD30升高与移植后时期循环中IL-10（白细胞介素-10）水平升高相关，但与IFN-γ水平无关。移植前sCD30和移植后第7天的sCD30均与肝移植受者的急性排斥反应无关。监测sCD30可能构成评估肾移植急性排斥反应风险的一种工具，但在本研究分析的一小部分肝移植受者患者中，它似乎并不是早期免疫监测的有价值手段。
